Evolving Concepts Regarding Radiation Therapy for Pancreatic Cancer
In todays practice most institutions individualize the use of adjuvant, neoadjuvant, and definitive RT based on their interpretation of the available data. This review highlights novel concepts and approaches to the use of RT that should be considered by the surgical oncologist. (Source: Surgical Oncology Clinics of North America)
Source: Surgical Oncology Clinics of North America - September 10, 2021 Category: Surgery Authors: William A. Hall, Beth Erickson, Christopher H. Crane Source Type: research

Hospital Volume Predicts Guideline Concordant Care in Stage III Esophageal Cancer
We examined the association of volume, program accreditation, safety net status, geographic region, patient travel distance on adequate adherence (≥85% of patients are adherent) using logistic regression modeling.RESULTS: The rate of adequate adherence was worst in nodal staging (12.6%) and highest for utilization of neoadjuvant therapy (84.8%). Academic programs had the highest rate of adequate adherence for induction therapy (77.2%, p
Source: The Annals of Thoracic Surgery - September 5, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Akash H Adhia Joseph M Feinglass Cary Jo Schlick Ryan P Merkow Karl Y Bilimoria David D Odell Source Type: research

Mesonephric adenocarcinomas in female genital tract: A case series
We report a series of MNACs arising from the vagina, cervix, uterine corpus, ovary, and fallopian tube, to summarize the clinical characteristics, pathological diagnosis, treatment, and prognosis. We retrospectively analyzed all MNACs in the female genital tract derived from our institute from January 2010 till January 2020. Patients’ clinical details and follow-up were obtained from hospital records and scans were obtained from picture archiving and communication system. A total of 11 patients were included. The median age of onset of symptoms was 52 years. All patients underwent total hysterectomy and bilat...
Source: Medicine - September 3, 2021 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Purpose: Neoadjuvant chemoradiation followed by surgery is the current standard of care in the treatment of locally advanced rectal cancer. Those who achieved pathologic complete response, following this standard of care, complete pathologic response (pCR) had better outcome. Until now there are no reliable clinical parameters to predict this response. The purpose of the study was to evaluate whether tumor volume may serve as a predictive factor in patients treated with neoadjuvant chemoradiotherapy. Materials and Methods: Between September 2015 and September 2019, patients diagnosed with stage IIA to IIIC recta...
Source: American Journal of Clinical Oncology - September 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research

Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe?
Conclusions: Our study revealed that there was no adverse pathologic or oncological outcome with the concurrent use of PPIs along with Cape-NACRT in the treatment of LARC. We report that it may be safe to use PPIs if essential, in this clinical setting, although it would be wise to exercise caution. (Source: American Journal of Clinical Oncology)
Source: American Journal of Clinical Oncology - September 1, 2021 Category: Cancer & Oncology Tags: Original Articles: Gastrointestinal Source Type: research

In Regard to Ying Li et al.
We read with interest the systematic review and meta-analysis by Li et al1 comparing lower and higher radiation doses for operable esophageal/gastroesophageal junction carcinoma. This is a topical article, with several other recent systematic reviews and meta-analyses reporting on high-dose relative to low-dose chemoradiation therapy.2,3 In contrast to some other meta-analyses, the article by Li et al reports that neoadjuvant chemotherapy with low-dose radiation therapy may offer superior overall survival, progression-free survival, toxicity, and distant failure rates compared with high-dose radiation therapy. (Source: Int...
Source: International Journal of Radiation Oncology * Biology * Physics - August 30, 2021 Category: Radiology Authors: Ronald Chow, Charles B. Simone Tags: Radiation Dose for Operable Esophageal/GEJ Cancer Source Type: research

In Reply to Chow and Simone
We thank Chow and Simone for their critical but helpful  comment1 on our manuscript.2 Their concerns were based on data on definitive concurrent chemoradiation therapy (dCRT) for inoperable esophageal carcinoma (EC) but not neoadjuvant concurrent chemoradiation therapy (nCRT) for operable patients. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - August 30, 2021 Category: Radiology Authors: Xin Yuan, Ying Li, Xudong Yin, Jiandong Tong, Zhengrong Zhang, Rui Wang, Yong Chen Source Type: research

In Regard to Ying Li et al.
We read with great interest the systematic review by Li et al.1 The authors found that a dose of 40.0 to 41.4 Gy with conventional fractionation (1.8-2.0 Gy daily) gave the best prognosis compared with other dose-fractionation schedules and recommended this radiation strategy for patients with operable esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ) receiving neoadjuvant concurrent chemoradiation therapy (nCRT). Because nCRT with a relatively wide dose range (41.4-50.4 Gy with 1.8-2.0 Gy per daily fraction) followed by surgery is a standard treatment for patients with resectable EC/GEJ according t...
Source: International Journal of Radiation Oncology * Biology * Physics - August 30, 2021 Category: Radiology Authors: Tao Wang, Guangyu Tian, Xiaojun Chen Source Type: research

In Reply to Wang et al.
We appreciate the opportunity to reply to the letter1 regarding  our manuscript.2 We strongly agree with the author's opinion concerning the reassessment of a preoperative radiation dose of more than 41.4 Gy for patients with operable esophageal cancer and carcinoma of the gastroesophageal junction (EC/GEJ) receiving neoadjuvant concurrent chemoradiation therap y (nCRT) because of the uncertain benefit of an additional 5 to 10 Gy escalation. Two important randomized trials (CROSS and NEOCRTEC5010 trial) using 41.4 or 40 Gy demonstrated promising data regarding numerically non-inferior survival compared with>41.4 Gy...
Source: International Journal of Radiation Oncology * Biology * Physics - August 30, 2021 Category: Radiology Authors: Xudong Yin, Ying Li, Jiandong Tong, Yong Chen Source Type: research

Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration
CONCLUSION: RP of initially rectum infiltrating PCa is feasible and safe after inductive NAT, however complications rates tend to be higher compared to standard RP.PMID:34456124 | DOI:10.1016/j.urolonc.2021.07.028 (Source: Urologic Oncology)
Source: Urologic Oncology - August 30, 2021 Category: Urology & Nephrology Authors: Benedikt Hoeh Felix Preisser Mike Wenzel Clara Humke Clarissa Wittler Jens K öllermann Boris Bodelle Simon Bernatz Thomas Steuber Derya Tilki Markus Graefen Pierre I Karakiewicz Andreas Becker Luis A Kluth Felix K H Chun Philipp Mandel Source Type: research

Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration
CONCLUSION: RP of initially rectum infiltrating PCa is feasible and safe after inductive NAT, however complications rates tend to be higher compared to standard RP.PMID:34456124 | DOI:10.1016/j.urolonc.2021.07.028 (Source: Urologic Oncology)
Source: Urologic Oncology - August 30, 2021 Category: Urology & Nephrology Authors: Benedikt Hoeh Felix Preisser Mike Wenzel Clara Humke Clarissa Wittler Jens K öllermann Boris Bodelle Simon Bernatz Thomas Steuber Derya Tilki Markus Graefen Pierre I Karakiewicz Andreas Becker Luis A Kluth Felix K H Chun Philipp Mandel Source Type: research

Immunotherapy for Non-melanoma Skin Cancer
AbstractPurpose of ReviewThe therapeutic landscape for non-melanoma skin cancer (NMSC) has recently expanded with the development of effective and targeted immunotherapy. Here, we provide an overview of the role of immunotherapy in the management of advanced cutaneous carcinomas.Recent FindingsSeveral agents were recently U.S. Food and Drug Administration (FDA)-approved for the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma, Merkel cell carcinoma, and basal cell carcinoma. However, recent approvals in tissue-agnostic indications may also benefit other NMSCs including cutaneous adnexal solid ...
Source: Current Oncology Reports - August 27, 2021 Category: Cancer & Oncology Source Type: research

The predictive value of PET/CT for distant recurrences in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
ConclusionIn conclusion, a PET/CT has the potential to better stratify patients of their risk of distant metastasis. However, a larger validation cohort is required before these findings can be translated to clinical utility. (Source: Journal of Medical Imaging and Radiation Oncology)
Source: Journal of Medical Imaging and Radiation Oncology - August 26, 2021 Category: Radiology Authors: Joseph C Kong, Jennifer Ryan, Timothy Akhurst, Samuel Y Ngan, Michael Michael, Jeanne Tie, Satish K Warrier, Alexander G Heriot Tags: Medical Imaging ‐Radiation Oncology—Original Article Source Type: research

Biological consequences of cancer radiotherapy in the context of oral squamous cell carcinoma
Approximately 50% of subjects with cancer have been treated with ionizing radiation (IR) either as a curative, adjuvant, neoadjuvant or as a palliative agent, at some point during the clinical course of their ... (Source: Head and Face Medicine)
Source: Head and Face Medicine - August 26, 2021 Category: ENT & OMF Authors: G. Feller, R. A. G. Khammissa, M. S. Nemutandani and L. Feller Tags: Review Source Type: research

Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
Advances in multi-modality treatment of locally advanced rectal cancer (LARC) have resulted in low local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel... (Source: Radiation Oncology)
Source: Radiation Oncology - August 26, 2021 Category: Cancer & Oncology Authors: Catherine R. Hanna, Sean M. O ’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacquelin Tags: Study protocol Source Type: research

Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres prescribed using the MIRD model for Intrahepatic Cholangiocarcinoma
To evaluate outcomes of intrahepatic cholangiocarcinoma (iCCA) patients undergoing neoadjuvant yttrium-90 transarterial radioembolization (Y90-TARE) with resin microspheres prescribed using the Medical Internal Radiation Dose (MIRD) model. (Source: Journal of Vascular and Interventional Radiology : JVIR)
Source: Journal of Vascular and Interventional Radiology : JVIR - August 25, 2021 Category: Radiology Authors: Ammar Sarwar, Aamir Ali, Damir Ljuboja, Jeffrey L. Weinstein, Anuradha S. Shenoy-Bhangle, Imad A. Nasser, Matthew K. Morrow, Salomao Faintuch, Michael P. Curry, Andrea J. Bullock, Muneeb Ahmed Tags: Clinical Study Source Type: research

Lessons Learned in Managing Patients with Colorectal Cancer During the COVID-19 Pandemic
Opinion statementThe COVID-19 pandemic forced us to rapidly and dramatically shift our medical priorities and decision making. With little literature or experience to rely on, the initial priority was to minimize patient exposure to the hospital and to others. It remains unclear whether cancer patients are at higher risk of infection or serious complications, or if it is our traditional therapies that place them to be at higher risk. By far, the greatest negative impact was on screening. Routine colonoscopies were considered elective, and as a result, delays in diagnosis will be felt for years to come. The most positive ch...
Source: Current Treatment Options in Oncology - August 23, 2021 Category: Cancer & Oncology Source Type: research

Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
This article discusses the NCCN Guidelines recommendations for favorable histology WT.PMID:34416707 | DOI:10.6004/jnccn.2021.0037 (Source: Journal of the National Comprehensive Cancer Network : JNCCN)
Source: Journal of the National Comprehensive Cancer Network : JNCCN - August 20, 2021 Category: Cancer & Oncology Authors: Frank Balis Daniel M Green Clarke Anderson Shelly Cook Jasreman Dhillon Kenneth Gow Susan Hiniker Rama Jasty-Rao Chi Lin Harold Lovvorn Iain MacEwan Julian Martinez-Agosto Elizabeth Mullen Erin S Murphy Mark Ranalli Daniel Rhee Denise Rokitka Elisabeth Li Source Type: research

Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer
The prevalence of pancreatic cancer is sharply increasing recently, which significantly increases the economic burden of the population. At present, the primary treatment of resectable pancreatic cancer is surgical resection, followed by chemotherapy with or without radiation. However, the recurrence rates remain high even after R0 resection. This treatment strategy does not distinguish undetected metastatic disease, and it is prone to postoperative complications. Neoadjuvant therapies, including neoadjuvant chemotherapy and radiotherapy, is being increasingly utilized in borderline resectable as well as resectable pancrea...
Source: Frontiers in Oncology - August 18, 2021 Category: Cancer & Oncology Source Type: research

Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: A matched cohort analysis
CONCLUSIONS: After matching for T-stage and other clinical variables, history of pelvic XRT for prostate cancer in patients who later required RC for bladder cancer, was not associated with an increased rate of perioperative complications or an independent predictor of RFS or OS.PMID:34400070 | DOI:10.1016/j.urolonc.2021.06.017 (Source: Urologic Oncology)
Source: Urologic Oncology - August 17, 2021 Category: Urology & Nephrology Authors: Prithvi B Murthy Zaeem Lone Dillon Corrigan Rebecca Campbell Carlos Munoz-Lopez Maxx Caveney Daniel Gerber Kyle J Ericson Lewis Thomas Jj H Zhang Jihad Kaouk Christopher Weight Ryan Berglund Georges-Pascal Haber Byron H Lee Source Type: research

Intimal sarcoma of the pulmonary artery treated with neoadjuvant radiation prior to pulmonary artery resection and reconstruction
We report a case of IS of the pulmonary artery diagnosed after an endarterectomy to remove a suspected pulmonary embolism. The tumor could not be entirely resected and showed interval growth at post-operative follow up. Neoadjuvant radiotherapy was then delivered to improve resectability. Imaging confirmed decreased tumor size, and a surgical resection with pulmonary artery reconstruction and right upper lobectomy was then successfully performed. Adjuvant gemcitabine and docetaxel was later initiated. Four months post-operatively, the patient is alive without disease recurrence. While prior reports in the literature docume...
Source: Respiratory Care - August 17, 2021 Category: Respiratory Medicine Authors: Alexander Allen Steven C Smith Raghavendra Pillappa Sosipatros Boikos Benjamin Medalion John Grizzard Anthony Cassano Timothy Harris Source Type: research

Survival outcomes following radical cystectomy in patients with prior pelvic radiation for prostate cancer: A matched cohort analysis
CONCLUSIONS: After matching for T-stage and other clinical variables, history of pelvic XRT for prostate cancer in patients who later required RC for bladder cancer, was not associated with an increased rate of perioperative complications or an independent predictor of RFS or OS.PMID:34400070 | DOI:10.1016/j.urolonc.2021.06.017 (Source: Urologic Oncology)
Source: Urologic Oncology - August 17, 2021 Category: Urology & Nephrology Authors: Prithvi B Murthy Zaeem Lone Dillon Corrigan Rebecca Campbell Carlos Munoz-Lopez Maxx Caveney Daniel Gerber Kyle J Ericson Lewis Thomas Jj H Zhang Jihad Kaouk Christopher Weight Ryan Berglund Georges-Pascal Haber Byron H Lee Source Type: research

MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity
This study evaluates breast MRI response of ER/PR+ HER2- breast tumors to pre-operative SABR with pathologic response correlation.METHODS: Women enrolled in a phase 2 single institution trial of SABR for ER/PR+ HER2- breast cancer were retrospectively evaluated for radiologic-pathologic correlation of tumor response. These patients underwent baseline breast MRI, SABR (28.5 Gy in 3 fractions), follow-up MRI 5 to 6 weeks post-SABR, and lumpectomy. Tumor size and BI-RADS descriptors on pre and post-SABR breast MRIs were compared to determine correlation with surgical specimen % tumor cellularity (%TC). Reported MRI tumor dime...
Source: Clinical Breast Cancer - August 13, 2021 Category: Cancer & Oncology Authors: R Jared Weinfurtner Natarajan Raghunand Olya Stringfield Mahmoud Abdalah Bethany L Niell Dana Ataya Angela Williams Blaise Mooney Marilin Rosa Marie C Lee Nazanin Khakpour Christine Laronga Brian Czerniecki Roberto Diaz Kamran Ahmed Iman Washington Michae Source Type: research

MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity
This study evaluates breast MRI response of ER/PR+ HER2- breast tumors to pre-operative SABR with pathologic response correlation.METHODS: Women enrolled in a phase 2 single institution trial of SABR for ER/PR+ HER2- breast cancer were retrospectively evaluated for radiologic-pathologic correlation of tumor response. These patients underwent baseline breast MRI, SABR (28.5 Gy in 3 fractions), follow-up MRI 5 to 6 weeks post-SABR, and lumpectomy. Tumor size and BI-RADS descriptors on pre and post-SABR breast MRIs were compared to determine correlation with surgical specimen % tumor cellularity (%TC). Reported MRI tumor dime...
Source: Clinical Genitourinary Cancer - August 13, 2021 Category: Cancer & Oncology Authors: R Jared Weinfurtner Natarajan Raghunand Olya Stringfield Mahmoud Abdalah Bethany L Niell Dana Ataya Angela Williams Blaise Mooney Marilin Rosa Marie C Lee Nazanin Khakpour Christine Laronga Brian Czerniecki Roberto Diaz Kamran Ahmed Iman Washington Michae Source Type: research

High-dose hypofractionated stereotactic body radiotherapy for spinal chordoma
CONCLUSIONS: Neoadjuvant high-dose, hypofractionated SBRT for spinal chordoma is safe and does not increase surgical morbidities. Early outcomes at 2 years are promising, although long-term follow-up is pending.PMID:34388713 | DOI:10.3171/2021.2.SPINE202199 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - August 13, 2021 Category: Neurosurgery Authors: Xuguang Chen Sheng-Fu L Lo Chetan Bettegowda Daniel M Ryan John M Gross Chen Hu Lawrence Kleinberg Daniel M Sciubba Kristin J Redmond Source Type: research

MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity
This study evaluates breast MRI response of ER/PR+ HER2- breast tumors to pre-operative SABR with pathologic response correlation.METHODS: Women enrolled in a phase 2 single institution trial of SABR for ER/PR+ HER2- breast cancer were retrospectively evaluated for radiologic-pathologic correlation of tumor response. These patients underwent baseline breast MRI, SABR (28.5 Gy in 3 fractions), follow-up MRI 5 to 6 weeks post-SABR, and lumpectomy. Tumor size and BI-RADS descriptors on pre and post-SABR breast MRIs were compared to determine correlation with surgical specimen % tumor cellularity (%TC). Reported MRI tumor dime...
Source: Clinical Breast Cancer - August 13, 2021 Category: Cancer & Oncology Authors: R Jared Weinfurtner Natarajan Raghunand Olya Stringfield Mahmoud Abdalah Bethany L Niell Dana Ataya Angela Williams Blaise Mooney Marilin Rosa Marie C Lee Nazanin Khakpour Christine Laronga Brian Czerniecki Roberto Diaz Kamran Ahmed Iman Washington Michae Source Type: research

MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity
This study evaluates breast MRI response of ER/PR+ HER2- breast tumors to pre-operative SABR with pathologic response correlation.METHODS: Women enrolled in a phase 2 single institution trial of SABR for ER/PR+ HER2- breast cancer were retrospectively evaluated for radiologic-pathologic correlation of tumor response. These patients underwent baseline breast MRI, SABR (28.5 Gy in 3 fractions), follow-up MRI 5 to 6 weeks post-SABR, and lumpectomy. Tumor size and BI-RADS descriptors on pre and post-SABR breast MRIs were compared to determine correlation with surgical specimen % tumor cellularity (%TC). Reported MRI tumor dime...
Source: Clinical Genitourinary Cancer - August 13, 2021 Category: Cancer & Oncology Authors: R Jared Weinfurtner Natarajan Raghunand Olya Stringfield Mahmoud Abdalah Bethany L Niell Dana Ataya Angela Williams Blaise Mooney Marilin Rosa Marie C Lee Nazanin Khakpour Christine Laronga Brian Czerniecki Roberto Diaz Kamran Ahmed Iman Washington Michae Source Type: research

High-dose hypofractionated stereotactic body radiotherapy for spinal chordoma
CONCLUSIONS: Neoadjuvant high-dose, hypofractionated SBRT for spinal chordoma is safe and does not increase surgical morbidities. Early outcomes at 2 years are promising, although long-term follow-up is pending.PMID:34388713 | DOI:10.3171/2021.2.SPINE202199 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - August 13, 2021 Category: Neurosurgery Authors: Xuguang Chen Sheng-Fu L Lo Chetan Bettegowda Daniel M Ryan John M Gross Chen Hu Lawrence Kleinberg Daniel M Sciubba Kristin J Redmond Source Type: research

High-dose hypofractionated stereotactic body radiotherapy for spinal chordoma
CONCLUSIONS: Neoadjuvant high-dose, hypofractionated SBRT for spinal chordoma is safe and does not increase surgical morbidities. Early outcomes at 2 years are promising, although long-term follow-up is pending.PMID:34388713 | DOI:10.3171/2021.2.SPINE202199 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - August 13, 2021 Category: Neurosurgery Authors: Xuguang Chen Sheng-Fu L Lo Chetan Bettegowda Daniel M Ryan John M Gross Chen Hu Lawrence Kleinberg Daniel M Sciubba Kristin J Redmond Source Type: research

High-dose hypofractionated stereotactic body radiotherapy for spinal chordoma
CONCLUSIONS: Neoadjuvant high-dose, hypofractionated SBRT for spinal chordoma is safe and does not increase surgical morbidities. Early outcomes at 2 years are promising, although long-term follow-up is pending.PMID:34388713 | DOI:10.3171/2021.2.SPINE202199 (Source: Journal of Neurosurgery.Spine)
Source: Journal of Neurosurgery.Spine - August 13, 2021 Category: Neurosurgery Authors: Xuguang Chen Sheng-Fu L Lo Chetan Bettegowda Daniel M Ryan John M Gross Chen Hu Lawrence Kleinberg Daniel M Sciubba Kristin J Redmond Source Type: research

Screening of MicroRNA Related to Irradiation Response and the Regulation Mechanism of miRNA-96-5p in Rectal Cancer Cells
In this study, we screened microRNAs (miRNAs) which were positively correlated with irradiation resistance and found that miRNA-552 and miRNA-183 families were positively correlated with the irradiation resistance of rectal cancer, and found that high expression of miRNA-96-5p enhanced the irradiation resistance of rectal cancer cells through direct regulation of the GPC3 gene and abnormal activation of the canonical Wnt signal transduction pathway. Based on the radioreactivity results of patient-derived xenograft models, this is the first screening report for radio-resistant biomarkers in rectal cancer. Our results sugges...
Source: Frontiers in Oncology - August 11, 2021 Category: Cancer & Oncology Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology : WJG - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
World J Gastroenterol. 2021 Jul 21;27(27):4383-4394. doi: 10.3748/wjg.v27.i27.4383.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that is best treated in a multidisciplinary fashion using surgery, chemotherapy, and radiation. Adjuvant chemotherapy has shown to have a significant survival benefit in patients with resected PDAC. However, up to 50% of patients fail to receive adjuvant chemotherapy due to postoperative complications, poor patient performance status or early disease progression. In order to ensure the delivery of chemotherapy, an alternative strategy is to administer systemic treatm...
Source: World Journal of Gastroenterology - August 9, 2021 Category: Gastroenterology Authors: Ahmad Hamad Zachary J Brown Aslam M Ejaz Mary Dillhoff Jordan M Cloyd Source Type: research